Magnabid
OperatingHealthcare · Beverly Hills, CA
Financials
FY2014–FY2017 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Fundraising history
Team
5 people
Ben Mansouri is Magnabid's full-time CTO and Treasurer since Inception and is a technology veteran with over 25 years of experience in developing software solutions for a wide range of companies. Prior to Magnabid, Ben has managed several software consulting companies and he has run Business Intelligence teams for companies such as SlickDeals, VCA, PeopleMedia. Ben pioneered PC software engineering programs in Iran and was named one of the best CTOs under 30. Positions and offices held within the past three years: - Synergy Technology, CTO, 2011-Present
Dr. Anita Sabeti has been Magnabid's president and Medical director since Inception. She is a prestigious, board-certified pediatrician and prior to joining Magnabid, Anita was president of Luminix- Teen Skin Centers where Laser Technologies was used to help countless teenagers with skin problems. She is an attending at Cedars Sinai Medical Center and worked as voluntary attending at Women’s and Children’s Hospital, Los Angeles. Anita is a graduate of LAC-USC pediatric residency program. Positions and offices held within the past three years: - Luminix Teen Skin Center, President, 2012-President - Best Care Pediatrics, President, 2005-Present
Pez Zarifian is Magnabid's CEO and Diretor since Inception and a systems engineer at NASA’s Jet Propulsion Laboratory (JPL). He has led a number of highly complex software development projects at JPL and other companies. While working at JPL, Pez orchestrated a small team to develop a prototype for a programmable educational robot for kids, called Quiby. Before joining JPL, Pez worked at University of Southern California's (USC's) Information Sciences Institute (ISI) , where he contributed to a number of technical projects. Pez is a USC graduate at Viterbi School of Engineering. Positions and offices held within the past three years: - Trapezoid Inc., CEO, 2016-Present
Dr. Rouzbeh Ahmadian is a Healthcare and MedTech consultant at McKinsey & Company. Rouzbeh has more than a decade of experience in clinical medicine with specialty training in general surgery and radiology. Rouzbeh is also a biomedical engineer and inventor with R&D expertise in customized medical device production using 3D printing. Since his MBA training at Northwestern Kellogg School of Management, Rouzbeh has been involved in MedTech entrepreneurship and venture capital, and has served as a technical adviser to several startups.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 10 annual reports (FY2016–FY2025)
Missing: 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGAR- Form C-USep 14, 20180001665160-18-000935EDGAR
- Form CJun 13, 20180001665160-18-000571EDGAR
- Form C-UJun 13, 20180001665160-18-000566EDGAR
- Form C-UJun 13, 20180001665160-18-000567EDGAR
- Form C/AApr 30, 20180001665160-18-000372EDGAR
- Form CMar 12, 20180001665160-18-000188EDGAR
- Form C-UAug 30, 20170001665160-17-000386EDGAR
- Form C/AAug 15, 20170001665160-17-000354EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.